Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRI-LEGEST FE vs NORTREL 0.5/35-21
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Tri-Legest FE is a combination oral contraceptive containing ethinyl estradiol and norethindrone acetate. It prevents ovulation by inhibiting gonadotropin release (FSH and LH) and alters cervical mucus and endometrial lining to impede sperm penetration and implantation.
Combination hormonal contraceptive containing norethindrone (a progestin) and ethinyl estradiol (an estrogen). Norethindrone inhibits ovulation by suppressing gonadotropin release (LH and FSH) and alters cervical mucus and endometrial receptivity. Ethinyl estradiol provides negative feedback on the hypothalamic-pituitary-ovarian axis, further suppressing ovulation.
Prevention of pregnancy
Prevention of pregnancy,Acne vulgaris (FDA-approved for moderate acne in women ≥15 years who have achieved menarche and desire contraception)
One tablet orally once daily for 28-day cycle: 21 days active tablets (norethindrone/ethinyl estradiol) followed by 7 days placebo. For contraception only.
1 tablet orally once daily for 21 days, followed by 7 days off. Each tablet contains 0.5 mg norethindrone and 35 mcg ethinyl estradiol.
Norethindrone: 7-8 hours; Ethinyl estradiol: 18 hours (terminal). Steady-state reached after 7 days; clinical contraceptive efficacy requires consistent dosing.
Norethindrone: terminal half-life approximately 7-8 hours. Ethinyl estradiol: terminal half-life approximately 13-27 hours, mean about 17 hours. Ethinyl estradiol exhibits a longer half-life due to enterohepatic recirculation and extensive tissue distribution.
No specific guidelines exist; use with caution in renal impairment due to potential for fluid retention and hyperkalemia.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment (GFR < 30 m L/min) due to potential for fluid retention and hyperkalemia.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age, especially in women over 35 years, and with number of cigarettes smoked. Women over 35 who smoke should not use combination oral contraceptives.
Pregnancy category X. Combination hormonal contraceptives (CHCs) are contraindicated in pregnancy. First trimester use may cause small increased risk of limb reduction defects and cardiovascular anomalies; second and third trimester exposure is associated with masculinization of female fetuses due to progestin component. Discontinue immediately if pregnancy occurs.
FDA Pregnancy Category X. Contraindicated in pregnancy. First trimester: Increased risk of congenital anomalies, including cardiac defects and limb reduction defects (odds ratio 1.5-2.0). Second and third trimesters: Risk of feminization of male fetus, hepatic adenoma, and other adverse effects. Exposure during pregnancy may increase risk of neurodevelopmental disorders.
Tri-Legest Fe is a combination oral contraceptive containing estradiol and norethindrone. Its 91-day extended-cycle regimen (84 active pills followed by 7 low-dose estrogen pills) reduces menstruation frequency to once every 3 months. Use caution in patients with migraine with aura, hypertension, or smoking over age 35 due to increased thromboembolic risk. The low-dose estrogen pills (10 mcg ethinyl estradiol) during week 13 help maintain hormone levels and reduce breakthrough bleeding. Advise patients to take at the same time daily; missed pills increase pregnancy risk.
NORTREL 0.5/35-21 is a combination oral contraceptive containing norethindrone 0.5 mg and ethinyl estradiol 35 mcg. It is a monophasic pill with 21 active tablets followed by 7 placebo tablets. Clinicians should note that the low-dose norethindrone may be less effective in preventing ovulation in some women, increasing the risk of breakthrough bleeding. This formulation is often used for cycle regulation and mild acne. Assess for contraindications including thrombotic disorders, migraine with aura, and smoking in women over 35.
No interactions on record
No interactions on record
TRI-LEGEST FE and NORTREL 0.5/35-21 are distinct pharmacological agents. TRI-LEGEST FE belongs to the Oral Contraceptive class and is primarily used for Prevention of pregnancy. NORTREL 0.5/35-21 belongs to the Oral Contraceptive class and is primarily used for Prevention of pregnancyAcne vulgaris (FDA-approved for moderate acne in women ≥15 years who have achieved menarche and desire contraception). Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. TRI-LEGEST FE carries a safety status of Category C, whereas NORTREL 0.5/35-21 safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Ethinyl estradiol is metabolized primarily by CYP3A4; norethindrone acetate is hydrolyzed to norethindrone, which is metabolized by reduction and conjugation (glucuronidation and sulfation).
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement; ethinyl estradiol: hepatic via CYP3A4, undergoes sulfation and glucuronidation. Both are excreted in urine and feces.
Renal: ~60% (metabolites), Fecal: ~30% (metabolites), Biliary: minor (~5% as conjugates)
Norethindrone is primarily excreted renally (approximately 60-80% as metabolites) and approximately 20-40% fecally. Ethinyl estradiol is excreted renally (about 40%) and fecally (about 60%) as glucuronide and sulfate conjugates.
Norethindrone: ~80% bound to SHBG and albumin; Ethinyl estradiol: >95% bound to albumin.
Norethindrone: 60-70% bound to albumin and SHBG. Ethinyl estradiol: 95-98% bound to albumin and 2-5% free; increases SHBG levels, which further affects norethindrone binding.
Norethindrone: 3-4 L/kg; Ethinyl estradiol: 2-3 L/kg. Indicates extensive tissue distribution.
Norethindrone: Vd approximately 4 L/kg (400 L/70kg), indicating extensive tissue distribution. Ethinyl estradiol: Vd approximately 2.5-4 L/kg (175-280 L/70kg), also widely distributed.
Oral: Norethindrone ~60% (first-pass metabolism); Ethinyl estradiol ~45-55% (first-pass and gut wall metabolism).
Norethindrone: oral bioavailability approximately 50-70% due to first-pass metabolism. Ethinyl estradiol: oral bioavailability approximately 40-50% due to first-pass metabolism.
Contraindicated in severe hepatic disease or active liver disease (Child-Pugh Class C). Use with caution in mild to moderate impairment (Child-Pugh A/B) without specific dose adjustment.
Contraindicated in acute hepatic disease, hepatic adenomas, or severe cirrhosis (Child-Pugh C). Use with caution in Child-Pugh A or B; dose adjustment not specifically defined, but monitor liver function.
Not indicated in premenarchal females; after menarche, same dosing as adults but only for contraception after assessment of skeletal maturity.
Not indicated for use before menarche. For post-menarchal adolescents, same dosing as adults: 1 tablet orally once daily for 21 days, then 7 days off.
Not indicated for use in postmenopausal women; no specific dose adjustments in elderly females of reproductive age.
Not indicated for use in postmenopausal women due to increased risk of cardiovascular events and venous thromboembolism. No specific dose adjustment in elderly; avoid use in women over 35 who smoke.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives. Women who use combination hormonal contraceptives should be strongly advised not to smoke, especially women over 35 years of age and those who smoke 15 or more cigarettes per day.
No significant food interactions. Grapefruit juice may slightly increase estrogen levels but not clinically meaningful. Avoid excessive alcohol intake as it may impair liver metabolism and increase risk of breakthrough bleeding.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels; avoid excessive intake. St. John's Wort and certain herbal supplements can reduce contraceptive efficacy. High-fat meals may slightly delay absorption but not significantly affect overall efficacy.
Small amounts of steroids pass into breast milk (M/P ratio unknown, estimated <1%). CHCs may reduce milk production and composition, especially with early postpartum use. Avoid use during lactation; progestin-only methods preferred. Use only if benefits outweigh risks.
Excreted in breast milk in small amounts (M/P ratio unknown for specific formulation; estrogen M/P ratio approximately 0.5, progestin variable). Can reduce milk production and composition. Generally not recommended; use alternative contraception if breastfeeding. Consider benefits versus risks.
Not applicable; combination hormonal contraceptives are contraindicated in pregnancy. No dose adjustments are recommended or studied. Discontinue immediately upon pregnancy diagnosis. Alternative contraception should be used if needed.
No dose adjustments as drug is contraindicated in pregnancy. Pharmacokinetic changes (increased volume of distribution, altered metabolism) are not relevant due to contraindication.
Take one pill daily at the same time; missing pills increases pregnancy risk.,You will have a period only once every 3 months (during the last week of each cycle).,Use backup contraception if you miss 2 or more active pills in a row.,Common side effects include spotting, nausea, breast tenderness, and mood changes.,Do not smoke while taking this medication, especially if over 35.,This does not protect against STIs; use condoms for prevention.,Inform your doctor if you have migraines, high blood pressure, or a history of blood clots.
Take one pill daily at the same time. Missing pills increases pregnancy risk.,Use backup contraception (e.g., condoms) for 7 days if you miss a pill, especially in the first week.,Common side effects include nausea, breast tenderness, and breakthrough bleeding, especially in the first few months.,Do not smoke while taking this medication, especially if over age 35, due to increased risk of blood clots.,This medication does not protect against HIV or other sexually transmitted infections.,Notify your provider if you experience severe headache, chest pain, leg swelling, or vision changes.,Store at room temperature away from moisture and heat.